No. The US has improved in some technical and scientific areas since COVID-19 but remains under-prepared for another pandemic or major health crisis due to persistent gaps in funding, stockpiles, workforce, supply chains, surveillance integration, and political/social cohesion.
Documented Strengths and Incremental Progress
•Scientific and platform advances: mRNA and other rapid-response vaccine/therapeutic platforms matured significantly. The US retains world-leading biomedical research capacity (NIH, academia, industry). Tools like wastewater surveillance expanded, and genomic sequencing capacity is higher than pre-2020. Experience with Operation Warp Speed-style coordination exists as a playbook.
•Some stockpile and industrial base work: The Strategic National Stockpile was partially rebuilt for certain PPE, antivirals, and vaccines after COVID shortages. Onshoring/friendshoring efforts for pharmaceuticals and precursors received attention, and Project NextGen (and similar efforts) aimed at next-generation broad coronavirus countermeasures.
•Legal and organizational tweaks: Updates to emergency authorities, CDC reorganization attempts, and after-action reviews produced recommendations. HHS, ASPR, and related entities have doctrines for response.
These are real but narrow. Capability on paper or in labs does not equal deployable, scalable response under stress.
Major Persistent Weaknesses
•Funding cliffs and under-investment in core public health: Many COVID-era surge funds expired or face cuts. Core CDC, state/local health department, and hospital preparedness budgets have historically been boom-bust; chronic underfunding of the public health workforce (vacancies, burnout, early retirements) continues. GAO and other oversight reports have repeatedly flagged incomplete implementation of recommended reforms. Hospital surge capacity (beds, staffed ICUs) is not robustly expandable without rationing, as elective care deferrals and traveler nurse markets showed.
•Supply chains and manufacturing: Heavy reliance on overseas production for APIs, PPE, syringes, and reagents remains a vulnerability. Just-in-time inventory practices in healthcare amplify shocks. Tests, diagnostics, and fill-finish capacity can still bottleneck.
•Surveillance, data, and early warning: Fragmented systems (federal/state, human/animal/environmental) hinder rapid detection and characterization—illustrated by uneven responses to H5N1 in dairy cattle, mpox clusters, and other threats. Privacy rules, incompatible IT, and incomplete genomic/epidemiologic sharing slow pictures of spread and variants. Global dependence on incomplete international reporting adds lag.
•Medical countermeasure development to deployment: Regulatory speed improved under emergency use, but peacetime friction, liability, cold-chain logistics, and equitable distribution planning lag. Therapeutics beyond monoclonals/vaccines (e.g., broad antivirals) and durable mucosal vaccines need more consistent prioritization. Stockpiles for novel threats are inherently limited.
•Workforce, hospitals, and non-pharmaceutical measures: Nursing/physician shortages, especially in high-intensity care, are structural. Public compliance with NPIs (isolation, masking, closures) is lower amid eroded trust; enforcement capacity and legal clarity vary sharply by jurisdiction. Long-term care, schools, and essential workforce protection plans remain uneven.
•Governance, trust, and polarization: Split federal-state authorities create coordination friction. Misinformation, declining confidence in CDC/FDA/public health (from multiple directions), and politicization of basic measures reduce voluntary compliance and increase noise. After-action honesty has been incomplete across administrations and agencies. International cooperation (information sharing, COVAX-like mechanisms, WHO reforms) is contested.
Evidence from Real Events and Assessments
Post-COVID reviews (Congressional, GAO, independent commissions, academic analyses) consistently describe partial remediation. Recent zoonotic spillovers (H5N1), antibiotic-resistant threats, and mpox showed detection delays, messaging inconsistency, and limited countermeasure depth. Modeling and tabletop exercises routinely reveal shortfalls in PPE burn rates, ventilator/oxygen scaling, and behavioral response. No serious expert body rates the US as fully prepared; most describe “better than 2019, far from resilient.”
Preparedness is not binary. High-income countries with strong biotech have advantages in countermeasures but share vulnerabilities in globalized supply, aging infrastructure, and open societies’ difficulty sustaining costly vigilance. Catastrophic scenarios (high-fatality respiratory pathogen with pre-symptomatic spread, or engineered threats) would stress systems harder than COVID.
What Would Improve Readiness
Sustained (not emergency-only) funding for workforce, stockpiles with rotation, domestic manufacturing surge capacity, integrated One Health surveillance, faster platform regulatory pathways, hospital resilience incentives, and ruthless after-action transparency. Reducing bureaucratic layering and restoring competence-focused trust matter as much as dollars. Innovation helps most when paired with logistics and execution.
In short, the US can develop tools faster than most and has absorbed hard lessons, but structural, fiscal, and social gaps mean another serious pandemic would again produce excess deaths, economic damage, and scrambling. Claims of full readiness are not supported by the record.